Prasol Chemicals Q2 FY27 Revenue at ₹413 Crore, Up 39% YoY
Prasol Chemicals reported its highest ever Q2 FY27 revenue of ₹413 crore, up 39% YoY. H1 FY27 revenue reached ₹846 crore, a 37% YoY increase. EBITDA surged 106.6% to ₹148 crore in H1 FY27, with PAT growing 138.9% to ₹99 crore. The company reaffirms its FY27 revenue guidance of ₹1,550-1,650 crore.
The announcement details record financial performance, substantial year-on-year growth across key metrics, and reaffirms future guidance, all of which are material for investors and stakeholders.
The company reported record revenue and significant year-on-year growth in both revenue and profit, indicating strong financial performance and positive business momentum.
Prasol Chemicals Limited announced its Q2 FY27 results, reporting the highest ever quarterly revenue of ₹413 crores, marking a significant year-on-year growth of 39%. For the first half of FY27 (H1 FY27), the company achieved a revenue of ₹846 crores, an increase of 37% year-on-year.
The Chairman, Mr. Nishith Shah, attributed the strong performance to better realisations and an improving product mix. Despite rising raw material prices, the company has been progressively increasing product prices and engaging with customers. Demand for Acetone-based and Phosphorus-based products remained healthy, although some export shipments faced delays due to higher freight costs and limited vessel availability amid the Middle East crisis.
In H1 FY27, EBITDA grew by 106.6% year-on-year to ₹148.0 crores, with a margin of 17.5%. Profit after tax for H1 FY27 was ₹99.0 crores, a substantial increase of 138.9% year-on-year. The company is progressing with its capex program and maintains a robust new product pipeline. Prasol Chemicals remains on track to meet its FY27 guidance of revenue between ₹1,550–1,650 crores and EBITDA between ₹240–250 crores.
What to do with a filing like this
Prasol Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Prasol Chemicals Limited. Read the original for the full detail.